title: Evaluation of cisplatin in combination with a biologic response modifier in a murine mammary carcinoma model.
abstract: The purpose of this study was to determine the efficacy of intracavitary cisplatin against local regrowth and metastasis after resection of a murine mammary carcinoma and the ability of a biologic response modifier (Virulizin) to enhance chemotherapy. C3H-HeJ mice were injected with Gollin-B tumor cells. Once growth reached 8 mm, tumors underwent marginal resection and the mice were assigned randomly to intraperitoneal (i.p.) cisplatin, Virulizin, a controlled release cisplatin-impregnated sponge (OPLA-Pt), a combination of treatments or no treatment and were evaluated for local regrowth, metastasis, and toxicity at 14 or 60 days after surgery. A possible beneficial interaction was seen between OPLA-Pt and Virulizin at 14 days. All cisplatin groups had significant advantages over controls in all variables measured with OPLA-Pt displaying significant advantages over i.p. cisplatin in local recurrence rate, tumor score, survival time, and delay in regrowth at 60 days. No toxicity related to either cisplatin or Virulizin was observed.
authors.affiliation: School of Veterinary Medicine of Torino, Torino, Italy.
authors.forename: Emanuela
authors.initials: E
authors.lastname: Morello
authors.forename: William S
authors.initials: WS
authors.lastname: Dernell
authors.forename: Charles A
authors.initials: CA
authors.lastname: Kuntz
authors.forename: Susan M
authors.initials: SM
authors.lastname: LaRue
authors.forename: Mary
authors.initials: M
authors.lastname: Lafferty
authors.forename: Ann
authors.initials: A
authors.lastname: Nelson
authors.forename: John H
authors.initials: JH
authors.lastname: Brekke
authors.forename: Craig H
authors.initials: CH
authors.lastname: Mallinckrodt
authors.forename: Stephen J
authors.initials: SJ
authors.lastname: Withrow
authors.forename: Mark C
authors.initials: MC
authors.lastname: Manning
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001646:Bile; D002945:Cisplatin / Q000627:therapeutic use*; D003692:Delayed-Action Preparations; D004359:Drug Therapy, Combination; D005260:Female; D007155:Immunologic Factors / Q000627:therapeutic use*; D007274:Injections, Intraperitoneal; D019344:Lactic Acid; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D051379:Mice; D008809:Mice, Inbred C3H; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000473:pathology; D011091:Polyesters; D011108:Polymers; D015996:Survival Rate; D014020:Tissue Extracts
chemical_list: D000276:Adjuvants, Immunologic; D000970:Antineoplastic Agents; D003692:Delayed-Action Preparations; D007155:Immunologic Factors; D011091:Polyesters; D011108:Polymers; D014020:Tissue Extracts; C087098:virulizin; D019344:Lactic Acid; C033616:poly(lactide); D002945:Cisplatin